Analyst Yun Zhong from Wedbush maintained a Buy rating on Ascendis Pharma and increased the price target to $220.00 from $212.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Yun Zhong has given his Buy rating due to a combination of factors that highlight Ascendis Pharma’s promising growth trajectory. The company has shown strong momentum with its product Yorvipath, despite not meeting consensus revenue expectations in the third quarter of 2025. The increase in unique patients and prescribers in the U.S. indicates a healthy growth pattern, and the addition of over 400 new patients in October alone underscores the product’s continued market penetration.
Furthermore, the company’s financial health is solid, with a significant cash reserve and positive cash flow reported for the quarter. The anticipated approval of TransCon CNP by the FDA, with no additional information requested, suggests a new commercial opportunity on the horizon. Additionally, the long-term clinical data supporting Yorvipath’s benefits, including improved renal function and patient compliance, further bolster the company’s outlook. These elements combined suggest a strong potential for revenue growth in the coming years, justifying the Buy rating.
In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $242.00 price target.